Uzbekistan Market Entry Strategy for Chinese Manufacturers: Registration Pathways and Compliance

1. Key takeaways

For Chinese manufacturers, the market access strategy for Uzbekistan can be summarized in three lines. First, use foreign approvals to buy time: devices that already hold approvals from the FDA, CE, PMDA, MFDS, MHRA, or EMA go through the recognition pathway, cutting the statutory review from 120 working days to 15 working days. Second, control long-term risk through the representative structure: select a local representative with electronic signature, vigilance response, and digital labeling capability, and consider a neutral third party for high-value equipment. Third, plan the system certificate backward from July 1, 2027: the national ISO:13485 conformity certificate is about to become a threshold requirement for the conformity certificate, and lead times for certification audits make early planning unavoidable. Each of the three lines depends on the others: recognition shortens entry, the representative sustains compliance, and the system certificate protects the position after 2027.

2. Legal basis

3. Expert insights

Insight 1: The value of the recognition pathway for Chinese manufacturers depends on what approvals are already in hand. The six categories of reference institutions listed in Resolution No. 738 are the United States FDA, European Union CE issuing bodies, the EMA, Japan PMDA, Korea MFDS, and the United Kingdom MHRA. Leading domestic companies that already hold these approvals can benefit directly; companies that do not yet hold them should prepare along the general pathway and place the acquisition of such approvals in their medium- and long-term plans. The same approvals serve multiple markets: they are not only a requirement for entering Europe, the United States, Japan, or Korea, but also the key that opens the Uzbekistan fast track. The reference list is closed, so approvals from authorities outside it do not shorten the review, whatever their quality.

Insight 2: Manage Uzbekistan separately from Russia and Kazakhstan. Uzbekistan is an observer state of the EAEU, not a member, and Russian RZN registration certificates, Kazakhstan registration certificates, and EAEU union registration certificates have no automatic effect here. Central Asian market planning should therefore split into an EAEU group and an Uzbekistan group: for the former, a single-certificate multi-country approach can be considered; for the latter, each project must be initiated separately, with its own dossier, its own representative, and its own timeline. A separate plan also prevents a common error: assuming that a union certificate obtained for Kazakhstan covers sales in Uzbekistan.

Insight 3: Four capabilities of the representative determine the sustainability of long-term compliance. The electronic signature, known as e-imzo, determines whether submissions can be completed at all; vigilance response capability determines whether the 1-day reporting deadline can be met; digital labeling operation capability determines whether codes can be applied before import; and MedDRA coding capability determines the cost of the quarterly aggregation. These four capabilities should be treated as hard screening criteria when selecting a representative, not as bonus items to be weighed against price. A representative strong in only two of the four capabilities can still leave the manufacturer exposed on the other two, so the assessment must cover all four explicitly.

Insight 4: Registration is only the beginning of access, and the 5-year validity turns compliance into a routine. The registration certificate is uniformly valid for 5 years, and previously issued certificates without an expiry have been converted. This means that post-market change management, renewal preparation, monitoring reports, and traceability maintenance are all long-term work. Companies that treat Uzbekistan as a one-off certification project encounter concentrated problems in years 4 and 5, precisely when renewal pressure and accumulated change history peak at the same time. Renewal planning should therefore start at least one review cycle before expiry, since the change history accumulated over five years must be reconciled at that point.

4. Practical recommendations

1. Verify recognition pathway eligibility product by product: an approval from one of the six categories of reference institutions, plus consistency across model, specification, manufacturing site, and intended use.
2. Place the acquisition of approvals from reference institutions such as the FDA and CE in the medium- and long-term plan, as a common key to multiple markets; the same dossier work also shortens reviews in other markets that recognize the same references.
3. Set four hard criteria for representative screening: electronic signature, vigilance response, labeling operations, and MedDRA coding.
4. Plan backward from July 1, 2027 for the national ISO:13485 conformity certificate, first checking whether any of the four exemption categories applies.
5. Build a 5-year cycle management register covering registration, changes, renewal, monitoring, and traceability, managed as one integrated program.

5. Verification checklist

• □ Recognition pathway eligibility has been verified product by product, covering the institution and the four consistency dimensions
• □ Acquisition of approvals from reference institutions has been included in the medium- and long-term plan
• □ Four hard criteria have been set for representative screening: electronic signature, vigilance response, labeling, and MedDRA
• □ The national ISO:13485 conformity certificate plan has been scheduled backward from 2027-07-01
• □ Applicability of the four exemption categories has been checked one by one
• □ The 5-year cycle management register covers registration, changes, renewal, monitoring, and traceability

Regulatory information verified as of October 29, 2026.

GRZAN provides regulatory support to manufacturers, importers, and authorized representatives seeking medical device registration and post-market compliance in Uzbekistan, including dossier preparation, authorized representative arrangements, vigilance setup, and surveillance readiness. For inquiries, contact info@grzanglobal.com.